Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.

Real-world data on the effectiveness of glecaprevir/pibrentasvir (GLE/PIB) for patients with HCV infection and compensated cirrhosis is limited, especially for the 8-week regimen and in an Asian population. This retrospective study enrolled 159 consecutive patients with HCV and compensated cirrhosis...

Full description

Bibliographic Details
Main Authors: Yung-Hsin Lu, Chung-Kuang Lu, Chun-Hsien Chen, Yung-Yu Hsieh, Shui-Yi Tung, Yi-Hsing Chen, Chih-Wei Yen, Wei-Lin Tung, Kao-Chi Chang, Wei-Ming Chen, Sheng-Nan Lu, Chao-Hung Hung, Te-Sheng Chang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0272567

Internet

https://doi.org/10.1371/journal.pone.0272567

Similar Items